XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business and Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 9 Months Ended
Jan. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Apr. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
Segment
Contract
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Aug. 31, 2019
USD ($)
Jul. 01, 2013
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Accumulated deficit         $ (3,199,522,000)   $ (3,130,069,000)    
Principal amount         278,800,000        
Cash and cash equivalents         54,308,000   124,184,000    
Short-term investments         110,738,000   79,932,000    
Long-term investments         12,728,000   56,619,000    
Financing liability         $ 104,000,000.0   100,500,000    
Debt issuance amount       $ 230,000,000.0          
Debt issuance percentage       2.50%          
Number of operating segment | Segment         1        
Purchase of available-for-sale investment         $ 5,000,000 $ 3,000,000      
Insulin                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Loss on purchase commitments         $ 70,200,000   82,800,000    
Loss on purchase commitments, number of new contracts recognized | Contract         0        
Maximum | AFREZZA product sales                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Sales return right following product expiration in months         12 months        
Minimum | AFREZZA product sales                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Sales return right following product expiration in months         6 months        
Convertible Promissory Note | Thirona Bio, Inc.                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Purchase of available-for-sale investment $ 5,000,000.0 $ 3,000,000.0              
Maturity date   2023-12              
Interest rate   6.00%              
MidCap Credit Facility                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Principal amount [1]         $ 40,000,000.0   $ 40,000,000.0    
Principal amount               $ 100,000,000.0  
Amount borrowed         40,000,000.0        
Principal prepayment against outstanding term loans     $ 10,000,000.0            
MidCap Credit Facility | Tranche Three                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Amount available under credit facility     $ 60,000,000.0 $ 25,000,000.0 60,000,000.0        
Milestone Rights Liability | Deerfield Management Company Lp                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Contingent liability remain payable         $ 60,000,000.0       $ 60,000,000.0
Milestone Rights Liability | Maximum | Deerfield Management Company Lp                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Contingent liability for milestone payments                 $ 90,000,000.0
[1]

In April 2021, the Company prepaid $10.0 million principal balance and amended the MidCap credit facility. The interest rate prior to the amendment was one-month LIBOR (2% floor) plus 6.75% and the maturity date was in August 2024.